When new compounds are sought to be used as drug candidates, they are named as NCEs, IICT sources said.
The CSIR-Indian Institute of Chemical Technology here said on August 16 that it has signed an agreement with pharma major SunPharma for "out-licensing of patents on a New Chemical Entity for multiple therapeutic indications".
When new compounds are sought to be used as drug candidates, they are named as NCEs, IICT sources said. As per the agreement, CSIR-IICT will get payments totaling Rs 240 crore, including upfront, development and regulatory and other payments, IICT said in a release.
"Further, the institute will also get payments from SunPharma through royalties on net sales on commercialization of the products developed using these patents," the release said.
SunPharma will be responsible for development, regulatory filings, manufacturing and commercialization of these potential products, it said.
Unlock 75% more savings this festive season. Get Moneycontrol Pro for a year for Rs 289 only.
Coupon code: DIWALI. Offer valid till 10th November, 2019 .